New pain cocktail could ease suffering after cancer amputation
NCT ID NCT07276867
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study compares two spinal anesthesia recipes for people having a leg amputated above the knee due to sarcoma (a type of cancer). One group gets the standard fentanyl plus bupivacaine, the other gets an added drug called dexmedetomidine. The goal is to see if the combo delays the need for rescue morphine after surgery. About 58 adults aged 18–60 are being enrolled in Egypt.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Dexmedetomidine and fentanyl
What this could lead to
If it works, this could point toward a better way to manage pain after leg amputation for sarcoma, reducing the need for strong painkillers like morphine.
What could go wrong
This is a small, early-stage trial with only 58 participants, so results may not apply to everyone. The added drug may not improve pain relief and could cause side effects like slow heart rate or low blood pressure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DEXMEDETOMIDINE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Cancer Institute
RECRUITINGCairo, 11796, Egypt
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact